A modular synthesis of tetracyclic meroterpenoid antibiotics by Wildermuth, Raphael et al.
ARTICLE
A modular synthesis of tetracyclic meroterpenoid
antibiotics
Raphael Wildermuth1, Klaus Speck1, Franz-Lucas Haut1, Peter Mayer1, Bianka Karge2, Mark Brönstrup 2
& Thomas Magauer1,3
Stachyﬂin, aureol, smenoqualone, strongylin A, and cyclosmenospongine belong to a family
of tetracyclic meroterpenoids, which, by nature of their unique molecular structures and
various biological properties, have attracted synthetic and medicinal chemists alike. Despite
their obvious biosynthetic relationship, only scattered reports on the synthesis and biological
investigation of individual meroterpenoids have appeared so far. Herein, we report a highly
modular synthetic strategy that enabled the synthesis of each of these natural products and
15 non-natural derivatives. The route employs an auxiliary-controlled Diels–Alder reaction to
enable the enantioselective construction of the decalin subunit, which is connected to var-
iously substituted arenes by either carbonyl addition chemistry or sterically demanding
sp2–sp3 cross-coupling reactions. The selective installation of either the cis- or trans-decalin
stereochemistry is accomplished by an acid-mediated cyclization/isomerization reaction.
Biological proﬁling reveals that strongylin A and a simpliﬁed derivative thereof have potent
antibiotic activity against methicillin-resistant Staphylococcus aureus.
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Meroterpenoids, which are derived from a mixedbiosynthetic terpenoid pathway, display a broadspectrum of biological activities and are equipped with
a wealth of structural complexity that originates from highly
sophisticated biosynthetic pathways1–9. The structurally-related
natural products stachyﬂin (1)10, aureol (2)8,11, smenoqualone
(3)12, strongylin A (4)13, cyclosmenospongine (5)14, and mama-
nuthaquinone (6)15 constitute a unique subclass of polycyclic
meroterpenoids that was previously harvested from marine and
fungal sources. Since the ﬁrst isolation of aureol in 1980,
considerable interest has arisen to prepare these complex natural
products by chemical synthesis and explore their biological
activities. Despite the successful synthesis of individual members
in a reasonable number of synthetic operations (10–27 linear
steps), none of the reported routes16–24 has enabled a practical
access to the whole family of these fascinating natural products
(Fig. 1).
Although scattered reports have revealed the antiviral
(1, 2, and 4)10,13,25, anticancer (2, 4, 5, and 6)13–15,26, and anti-
biotic (2)27 activities of several members of these natural
products, an exhaustive biological screen of 1–6 and fully syn-
thetic derivatives is still unavailable. So far, only a preliminary
structure–activity relationship (SAR) study of semi-synthetic
analogs of stachyﬂin (1) has been reported, revealing that subtle
modiﬁcations of the aromatic isoindolinone component have a
drastic effect on the observed H1N1 activity28–32. Here, we
address these limitations and describe a highly modular synthetic
platform for the construction of six natural products and 15
fully synthetic molecules that were previously inaccessible using
semi-synthesis. Biological proﬁling reveals that this class of
meroterpenoids has potent antibiotic activity against methicillin-
resistant Staphylococcus aureus.
Results
Total synthesis of (+)-stachyﬂin (1). As illustrated in Fig. 2a,
recent efforts by our group enabled a highly convergent and
scalable route to the trans-decalin-containing natural product
cyclosmenospongine (5). The developed synthesis proceeds via
the intermediacy of 5-epi-aureol (9) and enabled production of
420 mg of 5 in a single batch33. However, all efforts to adapt this
strategy for the construction of the cis-decalin subunit of 1–4
were unsuccessful.
We envisioned the synthesis of 1–6 by employing the highly
convergent strategy depicted in Fig. 2b. For the retrosynthetic
analysis, 1–6 were ﬁrst traced back to their protected forms I and
II. The carbon–oxygen bond disconnection at C10 leads to
the 5,6-dehydrodecalin precursor III, which would enable the
crucial late-stage assembly of either the cis- (kinetic product) or
trans-decalin (thermodynamic product) by an acid-promoted
isomerization/cyclization sequence. This event sets the remaining
two of four consecutive stereocenters. To account for maximum
modularity and convergence, we opted to break down III further
into the simple building blocks phenol IV, diene V, and tiglic
acid-derived dienophile VI using a sp2–sp3 cross-coupling (or
nucleophilic addition) and an exo-selective, auxiliary-controlled
Diels–Alder reaction that was described in seminal work by
Danishefsky34 and Minnaard35.
We began our investigations with the synthesis of stachyﬂin (1)
which contains a rare isoindolinone subunit (Fig. 3a)36. As initial
efforts to construct intermediate 15 according to a previously
reported protocol37 were low yielding and not reproducible on a
large scale, we set out to develop a more robust route. Our
synthesis begins with a solvent-free Alder–Rickert reaction
between the dimedone-derived bis-trimethylsilyl enol ether 10
and dimethyl 2-butynedioate (DMAD)38 to afford resorcinol 11
(86%). Careful monitoring of the reaction progress enables
mono-methylation (Me2SO4, K2CO3, acetone) of 11 to furnish
phenol 12 as a white crystalline solid in 73% yield. Exposure of 12
to a solution of 3,4-dimethoxybenzylamine (DMBNH2) and
trimethylaluminum (Me3Al) effected clean conversion to the
corresponding N,N-3,4-dimethoxydibenzyl phthalamide. The
subsequent formation of imide 13 was induced by heating the
neat phthalamide at 210 °C under reduced pressure (1 mbar)
with simultaneous removal of the liberated N,N-3,4-dimethox-
ydibenzyl amine. While bromination (Br2, CH2Cl2 or Br2,
AcOH) of 13 gave predominately the para-substituted phenol,
exclusive formation of 14 occurred upon treatment with
substoichiometric amounts of both iodine (0.6 equiv.) and
periodic acid (0.2 equiv.)39. Treating a solution of 14 in
tetrahydrofuran (1.0 M) in a sealed tube with borane tetrahy-
drofuran complex (3.0 equiv.) and substoichiometric quantities of
sodium borohydride (0.05 equiv.) at elevated temperature (70 °C)
effected regioselective reduction of the imide40. This protocol was
crucial to obtain the product as a single regioisomer in high yield.
Protection of the free phenol as its methoxymethyl ether
completed the synthesis of isoindolinone 15 (435 mg). The
overall sequence to 15 proceeds in six steps and involves only
crystalline intermediates, thus making it practical on a large scale.
We then focused on the construction of the 5,6-dehydrodecalin
component 25 by employing Fan auxilliary-controlled exo-
selective Diels–Alder cycloadditon between diene 20 and tiglic
acid-derived dienophile 21 (Fig. 3b).
Although the utility of 21 was previously demonstrated by
Minnaard for the synthesis of 1-tuberculosinyl adenosine35, we
were uncertain about the capability of 21 to override the inherent
substrate selectivity of 20 and the extent of steric hindrance
resulting from the benzyl ether at C3. Diene 20 was prepared from a
known β-hydroxyketone 1741 via a three-step sequence involving
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Fig. 1 Selected members of polycyclic meroterpenoids and their reported
biological activity. Within this subclass of natural products, two distinct
stereochemistries with respect to the decalin subunit have been noted.
While compounds 1–4 possess a cis-decalin, cyclosmenospongine (5)
features a unique trans-decalin scaffold. Both stereochemistries might
biosynthetically originate from a 5,6-dehydrodecalin framework as present
in mamanuthaquione (6). Color coding: blue, cis-decalin; green, trans-
decalin
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the formation of the benzyl-protected ketone 18, conversion to the
vinyltriﬂate 19, and Stille coupling (vinylSn(n-Bu3), Pd(PPh3)4,
LiCl, THF, 75 °C) to install the diene motif. Initial attempts to
promote the reaction between 20 and 21 conﬁrmed our concerns
that 21 is reluctant to undergo cycloaddition under standard
conditions (Me2AlCl, (CH2Cl)2, –40 °C to 23 °C). In order to
overcome the low reactivity of 20, we ﬁrst subjected the reactants
solution to high pressure (14 kbar, 23 °C, Me2AlCl, CH2Cl2)42.
Although the formation of the desired Diels–Alder product 22 was
observed under these forcing conditions, the product yield was low
due to competing decomposition to an intractable mixture of
products. However, the relative stereochemistry of 22 could be
validated by single-crystal structure analysis. After further optimi-
zation, we found that 22 could be reproducibly obtained in a good
yield and excellent diastereoselectivity (dr = 13:1) by conducting the
cycloaddition in 1,2-dichloroethane in a sealed tube and slowly
warming the reaction mixture from –40 °C to 23 °C. In this context,
it is important to note that the chiral auxiliary fully overrides the
substrate selectivity and the observed diastereoselectivity corre-
sponds to the optical purity of 20 (83% ee). Further conversion of
22 to iodide 25 via the intermediacy of thioester 23 and alcohol 24
proceeded smoothly to provide 2.3 g of 25 in a single batch.
With both components in hand, we turned our attention to the
critical linkage of 15 to 25 (Fig. 4). This process was expected to
be exceptionally challenging as it requires carbon–carbon bond
formation between C15, which resides at a sterically hindered
neopentylic position and C16, itself ﬂanked by two alkyl ether
substituents of the arene. From an evaluation of different
coupling strategies and based on our recent success to realize
challenging carbon–carbon bond formations43, a sp2–sp3 Negishi
cross-coupling reaction44 emerged as the method of choice. To
this end, we subjected both coupling partners to an exhaustive
screen of reactions conditions (see Supplementary Table 1). We
found that the coupling could be efﬁciently mediated by treating a
solution of 25, Pd-SPhos G2 (20 mol%), and SPhos (20 mol%)44
in tetrahydrofuran and N,N-dimethylacetamide (2:1) with the
organozinc species derived from 15. The use of N,N-
dimethylacetamide as a co-solvent and slightly elevated tempera-
ture (40 °C) were crucial to reproducibly observe full conversion,
short reaction times, and acceptable yields (56%).
Having prepared the 5,6-dehydrodecalin intermediate 26
(330 mg), the stage was set to investigate the key-
transformation for the installation of the cis-decalin framework.
This step was inspired by a previous work on effect-related
cascade cyclizations45 and was realized by ﬁrst cleaving the
methoxymethyl ether in 26. The so-formed phenol was unstable
upon standing and therefore was directly exposed to boron
triﬂuoride etherate at –40 °C. Slowly raising the temperature to
–15 °C over a period of 1 h led to full consumption of the phenol.
Although the mechanism of this cyclization reaction is still
unclear, it may be that protonation of the alkene ﬁrst affords the
C5 carbocation 27. Whether this directly undergoes stereospeciﬁc
1,2-hydride shift to give the C10 carbocation 29 or involves
the intermediacy of the C5–C10 alkene 28 is uncertain at this
point. At temperatures below –15 °C, trapping of the cation
by the phenol is kinetically controlled to exclusively provide the
cis-decalin. The use of the secondary benzyl-protecting group and
maintaining temperatures below –15 °C proved to be essential to
minimize ionization of the C3 position and undesirable ring
contraction (see Supplementary Methods and Supplementary
Fig. 61). Hydrogenolysis of the cyclization product facilitated
puriﬁcation and afforded 30 in 62% yield. For the completion
of the synthesis of 1, the DMB group was removed oxidatively
using previously reported conditions (PIFA, benzene)46. Finally,
cleavage of the methyl ether with potassium n-dodecanethiolate
(n-C12H24SK) in N,N-dimethylformamide (DMF) at 140 °C
proceeded smoothly to afford (+)-stachyﬂin (1). Spectroscopic
data (1H NMR13,C NMR, optical rotation) were found to be
identical with those reported for natural 110.
Total synthesis of natural products 2–6. Having established a
convergent and scalable synthesis of tetracyclic meroterpenoids
bearing a cis-fused decalin system, we set out to modify the route
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Fig. 2 Strategies for the construction of tetracyclic meroterpenoids. a The polyene cyclization reaction of aryl enol ether 7 enabled rapid assembly of the
trans-decalin substructure of 5-epi-aureol (9) and cyclosmensopongine (5). However, this strategy could not be adapted for the preparation of
meroterpenoids containing a cis-decalin subunit. b Synthesis of the 5,6-dehydrodecalin intermediate III should be accomplished by a highly modular, three-
component coupling strategy of phenol IV, diene V, and dienophile VI. The ability to construct both cis- and trans-decalins from a common precursor would
allow for the synthesis of 1–6 and a variety of non-natural derivatives for biological screening. Color coding: blue, cis-decalin, green, trans-decalin. R1= alkyl,
R2=H or OBn, Xc= chiral auxiliary
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in order to incorporate selective modiﬁcations and expand our
library of natural and non-natural analogs. For the asymmetric
synthesis of 2–6, which are derived from the common 3-deoxy-
5,6-dehydrodecalin subunit 33, we utilized the previously repor-
ted two-step sequence by Minnaard (Fig. 5)35. Thioester 32
underwent smooth Fukuyama reduction47 to give aldehyde 33,
whose relative stereochemistry was validated by single-crystal
structure analysis (see Supplementary Fig. 62). Pleasingly, the use
of the less sterically demanding arene component 3448 enabled
replacement of the previously required sp2–sp3 cross-coupling
reaction and thus simpliﬁed the installation of the crucial
C15–C16 carbon–carbon bond. The ortho-directed lithiation of
34 followed by 1,2-addition to 33 gave a mixture of diaster-
eoisomeric benzyl alcohols. Application of the two-step
Barton–McCombie deoxygenation protocol (CS2, MeI,
NaHMDS, then AIBN, n-Bu3SnH, 90 °C)49 reproducibly pro-
vided 35 in good yield (72%). For the completion of the synthesis
of aureol (2), both methoxymethyl ethers of 35 were ﬁrst cleaved
upon exposure to hydrochloric acid in methanol. The resulting
hydroquinone was prone to oxidation and therefore was
not puriﬁed but directly subjected to the optimized cyclization
conditions (BF3·OEt2, CH2Cl2, –40 °C to –10 °C) to afford 193 mg
of (+)-aureol (2) in a single batch. From there, the non-natural
5-epi-derivative 9 was prepared by thermal isomerization of the
cis-decalin using hydroiodic acid in benzene at 90 °C (87%)50.
In addition, cyclosmenospongine (5) was accessible by
subjecting 9 to our previously developed functionalization
sequence33. In a similar vein, mamanuthaquinone (6) was
synthesized by the coupling between 33 and arene 36 to give
37. Compound 37 was deprotected and then oxidized (salcomine,
O2) to give 6, which slowly decomposed upon storage at –20 °C.
Having demonstrated the generality and versatility of
the developed modular synthetic platform, further structural
modiﬁcations could be efﬁciently made by simple variation of
the arene and decalin component, and adjustment of the
cyclization conditions. While kinetic conditions (BF3·OEt2,
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Fig. 3 Synthesis of the isoindolinone component 15 and the dehydrodecalin 25. a The developed de novo synthesis of isoindolinone 15 proceeds in six linear
steps and only involves crystalline intermediates. b For the construction of the 5,6-dehydrodecalin 25, an auxiliary-controlled exo-selective Diels–Alder
cycloaddition was employed. This allowed the production of 25 in eight steps in gram quantities in a single batch. DMAD dimethyl acetylenedicarboxylate,
n-Bu n-butyl, Bn benzyl, DMB 3,4-dimethoxybenzyl, DMF N,N-dimethylformamide, LHMDS lithium hexadimethylsilazide, MOM methoxymethyl, Ms
methanesulfonyl, TBAI tetrabutylammonium iodide, Tf triﬂuoromethanesulfonyl, THF tetrahydrofuran
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CH2Cl2, –40 °C to –10 °C) gave the cis-decalin framework
exclusively, equilibration under thermodynamic conditions (HI,
benzene, 90 °C) afforded the trans-decalin as the only
stereoisomer.
In this manner, (+)-smenoqualone (3) and (+)-strongylin A (4),
and 15 fully synthetic tetracyclic analogs that were previously
inaccessible via semi-synthesis could be prepared (Fig. 6 and
Supplementary Methods). With the synthetic natural products
1–5 as well as the analogs 9 and 38–51 at hand, a basic
phenotypic bioproﬁle of meroterpenoids was recorded in
antibacterial and antiproliferative assays. Antimicrobial activities
were tested against members of the ESKAPE panel51, consisting
of the gram-positive bacteria methicillin-resistant Staphylococcus
aureus (MRSA) and Enterococcus faecium, the gram-negative
bacteria Escherichia coli, Pseudomonas aeruginosa, Acinetobacter
baumannii, and Klebsiella pneumonia, and the yeast fungus
Candida albicans. All compounds proved to be inactive against
gram-negative pathogens and C. albicans. However, several
analogs inhibited the growth of the MRSA-type strain DSM
11822 and the MRSA clinical isolate RKI 11-02670 with the
following SARs (Fig. 6 and Supplementary Table 21): the highest
activities were observed for 40, with EC50 values of 0.2 and 0.6
μM against DSM 11822 and RKI 11-02670, respectively, and for
strongylin A (4), which was active with EC50 values of 1 and 1
μM. Surprisingly, the combination of the heteroatom function-
alities of 4 and 40 led to a pronounced drop of activity, as
demonstrated by 3-hydroxy-strongylin (48) (83/49 μM). Related
compounds with 3-hydroxy function and a para-quinone unit
like 49 or a heterocycle as found in stachyﬂin (1), 43 and 44 had
also had little or no activity. In line with this, a non-hydroxylated,
contracted cyclopentene ring, as present in the stachyﬂin analog
39, led to re-gained activity (6/8 μM). On the other hand, a lack of
functionalities at the decalin and aromatic subunit also led to
inactive compounds, as demonstrated by 41 and 42. While the
mono-hydroxylated aureol 2 exhibited a potency (5/5 μM)
comparable to 4, the oxidation of the methylated hydroquinone
to a para-quinone as present in 46 was associated with a
pronounced drop of anti-MRSA activity to 33/20 μM. A clear
activity ranking for a cis- vs. trans-conﬁguration of the decalin
ring was not evident: the trans isomer was more potent in the 46
vs. 47, 3 vs. 51, and 5 vs. 50 pairs, while the opposite was true for
the 4 vs. 45 and the 43 vs. 44 pairs. The antiproliferative activities
of the compounds in the four mammalian cell lines L929, KB-3-1,
MCF-7, and FS4-LTM were tested using a WST-1 assay that
quantiﬁes the metabolic activity of the cell population (Supple-
mentary Table 22). The highest activities were observed for 40
(EC50 values of 7–14 μM) and 49 (EC50 values of 8–21 μM), both
hydroxylated at the C3 position. The observation that the SAR
did not parallel the antimicrobial activity suggests that a
separation of antibiotic and cytotoxic activities is possible, and
an even larger split may be obtained by further structural
optimization.
Discussion
In summary, we established a highly modular and robust syn-
thetic platform for the construction of variously substituted
meroterpenoid scaffolds. Our efforts culminated in the enantio-
selective total syntheses of (+)-stachﬂin (1), (+)-aureol (2),
(+)-smenoqualone (3), (+)-stronglin A (4), (–)-cyclosmenos-
pongine (5), and (–)-mamanuthaquinone (6). Key steps include
an asymmetric Diels–Alder reaction to install the 4,5-dehy-
drodecalin framework, either a highly efﬁcient sp2–sp3-Negishi
cross-coupling reaction or a nucleophilic addition reaction to
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Fig. 4 Component coupling and total synthesis of (+)-stachyﬂin (1). The sp2–sp3 Negishi cross-coupling reaction between arene 15 and iodide 25 provided
the precursor for the intended cyclization reaction. Promotion of this step was accomplished by the addition of excess boron triﬂuoride etherate (10 equiv.)
at low temperature (–40 °C) to exclusively produce the cis-decalin 30. At temperatures exceeding –15 °C, competing ionization of the C3 position and ring-
contraction prevailed (byproduct not shown, see Supplementary Methods). t-BuLi tert-butyllithium, DMA N,N-dimethylacetamide, PIFA phenyliodine bis
(triﬂuoroacetate), SPhos 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl, SPhos-Pd G2 chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)
[2-(2′-amino-1,1′-biphenyl)]palladium(II)
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forge the crucial C15–C16 carbon–carbon bond, and an acid-
mediated cyclization to selectively generate either stereoisomers
of the decalin subunit. Simultaneous structural variation of more
than one coupling component leads to rapid expansion of the
compound library. The library of natural and fully synthetic
molecules obtained so far was screened against a panel of bac-
terial pathogens and mammalian cell lines. Notably, the pro-
nounced antibiotic activity of 40, (+)-strongylin A (4), and
(+)-aureol (2) against MRSA in the low-μM range appears pro-
mising. The reported SAR suggests that a further enhancement of
activity is possible, e.g., through modiﬁcations at the aromatic
ring, and such modiﬁcations enabled by the described synthetic
platform.
Methods
NMR spectroscopy. NMR spectra were measured on a Bruker Avance III HD
(400MHz for proton nuclei, 100MHz for carbon nuclei) spectrometer equipped
with a CryoProbeTM, Bruker AXR300 (300MHz for proton nuclei, 75MHz for
carbon nuclei), Varian VXR400 S (400MHz for proton nuclei, 100 MHz for carbon
nuclei), Bruker AMX600 (600MHz for proton nuclei, 150MHz for carbon nuclei),
or Bruker Avance HD 800 (800 MHz for proton nuclei, 200 MHz for carbon
nuclei). Proton chemical shifts are expressed in parts per million (ppm, δ scale)
and the residual protons in the NMR solvent (CHCl3, δ = 7.26 ppm; C6D5H,
δ = 7.16 ppm; DMSO-d6, δ = 2.50 ppm) were used as internal reference. Carbon
chemical shifts are expressed in parts per million (δ scale, assigned carbon atom)
and the residual solvent peaks (CDCl3, δ = 77.16 ppm; C6D6, δ = 128.06 ppm;
DMSO-d6, δ = 39.52 ppm) were used as internal reference. The NMR spectroscopic
data are reported as follows: chemical shift in ppm (multiplicity, coupling constants
J (Hz), integration intensity) for 1H NMR spectra and chemical shift in ppm for
13C NMR spectra. Multiplicities are abbreviated as s (singlet), br s (broad singlet),
d (doublet), t (triplet), q (quartet), and m (multiplet). Signals in the NMR spectra
were assigned by the information obtained from 2D NMR experiments: homo-
nuclear correlation spectroscopy (COSY), total correlation spectroscopy (TOCSY),
heteronuclear single quantum coherence (HSQC), and heteronuclear multiple
bond coherence (HMBC). The software MestReNOVA 11.0 from Mestrelab
Research S. L was used to analyze and process all raw ﬁd ﬁles.
Mass spectrometry. High resolution mass spectra (HRMS) were measured at the
Department of Chemistry, Ludwig-Maximilians-University Munich, on the fol-
lowing instruments by electron impact (EI) or electron spray (ESI) techniques:
MAT 95 (EI) and MAT 90 (ESI) from Thermo Finnigan GmbH.
IR spectroscopy. Infrared spectra (IR) were recorded on a PerkinElmer Spectrum
BX II FT-IR system from 4000 to 600 cm–1. Substances were directly applied on the
ATR unit as a thin ﬁlm or a thin powder layer. The data are represented as
frequency of absorption (cm−1).
Optical rotation. Optical rotation values were recorded on a PerkinElmer 241 or
Anton Paar MCP 200 polarimeter. The speciﬁc rotation is calculated as follows:
½αφλ ¼ α½   100  c1  d1. The wave length λ is reported in nm (sodium D line, λ
= 589 nm), the measuring temperature ϕ in °C; α represents the recorded optical
rotation, c the concentration of the analyte in g mL−1, and d the length of the
cuvette in dm. Thus, the speciﬁc rotation is given in 10−1 deg cm2 g−1. The values
for the speciﬁc rotation are reported as follows: speciﬁc rotation (concentration
g 100 mL−1; solvent).
Melting points. Melting points were determined on a B-450 melting point
apparatus from BÜCHI Labortechnik AG.
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Fig. 5 Chemical synthesis of (+)-aureol (2), (–)-cyclosmenospongine (5), (–)-mamanuthaquinone (6), and (+)-5-epi-aureol (9). The 3-deoxy-5,6-
dehydrodecalin unit 33 was accessed in three steps from the known coupling of 21 and 31. Installation of the C15–C16 carbon–carbon bond was
accomplished by ortho-directed lithiation of 34 or 36 and nucleophilic addition to 33. AIBN azobisisobutyronitrile, NaHMDS sodium hexadimethylsilazide,
TMEDA N,N,N,N′-tetramethylethylenediamine
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Fig. 6 Extension of the modular synthetic platform. Structural variation of the arene and decalin component enabled rapid extension of the natural products
library and provided access to several non-natural analogs that were previously inaccessible via semi-synthesis. Each of the shown molecules depicted was
prepared in seven or fewer steps starting from iodide 25 or aldehyde 33. Color coding was used to indicate the decalin stereochemistry (coding: blue,
cis-decalin; green, trans-decalin) and to highlight the modiﬁed arene component. The effective concentrations (EC50 values) that inhibited the growth of
two MRSA strains (DSM 11822/RKI 11-02670) are given in μM
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Data availability. CCDC 1534418 (15), 1534416 (22), and 1534618 (33) contain
the supplementary crystallographic data for this paper. These data can be obtained
free of charge from the Cambridge Crystallographic Data Centre. The authors
declare that all the data supporting the ﬁndings of this study are available within
the article (and its supplementary information ﬁles).
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